38 results
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
rate in effect as of December 31, 2022 (£1/$1.2103).
Amount shown reflects cash bonuses awarded for achievement of performance goals.
Amounts reflect … of performance goals determined in accordance with our annual bonus plan. We currently contribute to Dr. Scots-Knight’s Self-Invested Personal Pension Scheme
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
standards designed to assure the product’s continued safety, quality and purity. Under the goals and policies agreed to by the FDA under the Prescription … review designations within six months of the filing date as compared to ten months under its current review goals.
Fast track designation
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
17 Oct 23
Current report (foreign)
7:01am
projected development goals in its expected timeframes, risks related to adverse side effects, risks related to reliance on third party partners
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
approvals, the ability of the company and Mereo BioPharma to successfully develop UX143, the company’s ability to achieve its projected development goals
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
development goals in its expected timeframes, risks related to adverse side effects, risks related to reliance on third party partners to conduct
6-K
EX-99.2
yhhjhi20xrjxu6cso tl
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
5v98jh1 fyvdvgy9g9v
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
S-8
EX-99.1
ynh qz9q92apptww7
15 Jan 21
Registration of securities for employees
4:21pm